Your Health, We Care
Enasidenib is an isocitrate dehydrogenase-2 inhibitor developed by Celgene Corporation in the United States and approved by the United States Food and Drug Administration (FDA) in 2017.
The FDA emphasizes that early recognition and aggressive management of differentiation syndrome is critical to reduce the risk of exacerbations and death.
